60 results about "Diabetic Eye Disease" patented technology

The invention discloses a medicinal composition for treating diabetes. The medicinal composition consists of astragalus, gardenia, Szechuan lovage rhizome, siberian solomonseal rhizome, finger citron, root of red-rooted salvia, cinnamomvine, swordlike atractylodes rhizome, white paeony root, perilla fruit, kudzuvine root, fragrant solomonseal rhizome, oyster shell, rehmannia root, Chinese angelica, common anemarrhena rhizome, honeysuckle flower, heartleaf houttuynia herb, fresh imperata root, Chinese caterpillar fungus, semen nelumbinis, siberian solomonseal rhizome, cornus fruit, prepared rehmannia root, villous amomum fruit, liquoric root, medlar, asparagus, black sesame, tuckahoe, cherokee rose fruit, cistanche deserticola, angelica dahurica, adenophora, dark plum fruit, complanate astragalus seed, cassia seed, mulberry leaf, fresh reed rhizome, mint, oriental waterplantain rhizome, wrinkled gianthyssop herb and parslane herb. The medicinal composition can control the blood sugar level of various patients who suffer from the diabetes and improve the clinical symptoms of diabetes complications effectively. Therefore the medicinal composition can be used for treating the diabetesand the diabetes complications such as diabetic gastroparesis, diabetic nephroma, diabetic foot, diabetic neuropathy, diabetic eye diseases and diabetic pruritus and the like.

The invention discloses a lutein ophthalmic preparation for protecting eyesight, which is prepared from the following raw materials: 5 to 13 parts of water-soluble lutein (based on C4oH56O2), 50 to 80 parts of taurine, 0.1 to 0.5 parts of selenium (based on Se), 10 to 25 parts of zinc (based on Zn), 0.5 to 1.0 part of water-soluble vitamin A, and 0.8 to 2.0 parts of glutathione; an auxiliary material consists of a diluent, a wetting agent, an isoosmotic adjusting agent, a preservative, an antioxygen and water for injection; formulations comprise eye drops, eye lotion and the like; and the lutein ophthalmic preparation is suitable for eye diseases such as myopia, long sight, cataract, glaucoma, retinal pigment degeneration, macular degeneration and the like. Various nutritious factors are reasonably compatible, a blank of a lutein external preparation is filled, and the bioavailability and health-care effect are obviously improved; and through actual application by 300,000 people, the total effective rate for the myopia, cataract and diabetic eye disease is over 90 percent and the lutein ophthalmic preparation has positive promotion valve.

The invention relates to the field of medicines and in particular relates to a silkworm pupa polypeptide 2 which can be used for preventing or treating diabetes mellitus. The sequence of the polypeptide 2 is PYERQADEPETKVTKKI. A preparation method of the polypeptide 2 comprises the following steps: (1) decoction; (2) enzymolysis; (3) protein separation; (4) separation and purification through semipreparative RP-HPLC (reverse phase high-performance liquid chromatography); (5) freeze-drying, wherein neutral protease and compound protease are adopted for enzymolysis; macroporous resin and sephadex are adopted for protein separation. The invention provides the application of the polypeptide 2 to treatment of diabetes mellitus and complications of diabetes mellitus, wherein the complications of diabetes mellitus include diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neuropathy. The silkworm pupa polypeptide 2 is extracted from silkworm pupae, has good safety and can be used for effectively preventing or treating diabetes mellitus.

The invention discloses a method for preparing cyclocarya paliurus extract with antioxidant activity and application with the cyclocarya paliurus extract as aldose reductase inhibitor. The method includes the steps of smashing, soaking, extracting and freeze drying. Compared with a traditional heat reflux extraction method, the ultrasonic extraction method which is adopted is less in effectively constituent damage, high in extraction rate, short in extraction time and low in energy consumption. The obtained extract has the good antioxidant and aldose reductase restraining effects, the restraining mechanism for the aldose reductase is an uncompetitive restraining mechanism, and the extract has the prospects of preventing or treating diabetic complications including diabetic nephropathy, diabetic neuropathy, diabetic eye diseases and the like. As natural extract, the cyclocarya paliurus extract has the advantages that the cyclocarya paliurus extract is fewer in side effect and high in safety and activity, and the process is simple and convenient.

The invention discloses a xanthophyll eye preparation for protecting the eyesight. The xanthophyll eye preparation is prepared from the following raw materials: 5-13 parts of water-soluble xanthophyll (metered based on C40H56O2), 50-80 parts of taurine, 0.1-0.5 part of selenium (metered based on Se), 10-25 parts of zinc (metered based on Zn), 0.5-1.0 part of water-soluble vitamin A and 0.8-2.0 parts of glutathione as well as auxiliary materials consisting of a diluting agent, a moistening agent, an isoosmotic adjusting agent, an anti-corrosive agent, an antioxidant and water for injection. The forms of the preparation include various eye preparations such as eye drops and eye lotions. The xanthophyll eye preparation is applicable to eye diseases such as shortsightedness, farsightedness, cataract, glaucoma, retinitis pigmentosa and macular degeneration. The xanthophyll eye preparation contains various nutritional factors which are reasonably combined, so that the blank of an external xanthophyll preparation is filled up and the bioavailability and the healthcare effect are remarkably improved; after being actually used by 300000 people, the xanthophyll eye preparation is proven to be above 90% in total effective rate in treating the shortsightedness, the cataract and diabetic eye diseases and is proven to have a positive promotional value.

The invention relates to the field of medicine and in particular relates to silkworm polypeptide 1 with capability of preventing or treating diabetes mellitus. The sequence of the silkworm polypeptide 1 is RLGRRLSEDPATPADQ. A preparation method of the silkworm polypeptide 1 comprises the following steps: (1) decocting; (2) enzymatic hydrolysis; (3) protein separation; (4) semi-preparative RP-HPLC separation and purification; and (5) freeze-drying, wherein papain and alkaline protease are adopted to carry out enzymatic hydrolysis; macroporous resin and sephadex are adopted to carry out protein separation. The invention also relates to application of the silkworm polypeptide 1 in treatment of the diabetes mellitus and complications of the diabetes mellitus. The complications of the diabetes mellitus include diabetic nephropathy, diabetic hypertension, diabetic eye disease and diabetic neurologic disorder. Since polypeptide is extracted from silkworm, the silkworm polypeptide 1 disclosed by the invention is good in safety and is capable of effectively preventing or treating the diabetes mellitus.

The present invention discloses an application of an oleanolic acid derivative and pharmaceutically acceptable salts thereof in diabetic eye disease treatment. The oleanolic acid derivative is prepared into a nanometer preparation, a microsphere preparation and a hydrogel by using a polymer, such that toxicity of the oleanolic acid derivative is substantially reduced, an administered dose is increased, the obtained drug can provide an effect in eyes, and can provide stronger therapeutic effects compared to ordinary preparations and other long-acting preparations of the oleanolic acid derivative, the effect can be lasted for a plurality of months, and is uniform, and the drug can provide treatment effects for various or most of diabetic eye diseases, and can be taken at the diabetic eye disease initial stage so as to relieve patient pain, such that pathogenetic condition deterioration can be avoided, and surgeries and other surgical treatment methods with heavy traumas can be avoided.

Compositions containing molecular dispersions of lipophilic nutrients and methods thereof are provided for delaying the development and maturation of eye related complications of diabetes by administering a composition containing lipophilic nutrients. More particularly, methods relate to delaying the development and maturation of eye related complications of diabetes by administering a composition containing lutein and its isomers, lutein ester, zeaxanthin isomers, turmeric extract, curcumin or curcuminoids, derived from plant extract / oleoresin containing xanthophylls / xanthophylls esters which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits.

Compositions containing molecular dispersions of lipophilic nutrients and methods thereof are provided for delaying the development and maturation of eye related complications of diabetes by administering a composition containing lipophilic nutrients. More particularly, methods relate to delaying the development and maturation of eye related complications of diabetes by administering a composition containing lutein and its isomers, lutein ester, zeaxanthin isomers, turmeric extract, curcumin or curcuminoids, derived from plant extract / oleoresin containing xanthophylls / xanthophylls esters which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits.

The invention relates to the field of drugs and particularly relates to an inhibitor 1 compound which can treat diabetes. A sequence of the inhibitor 1 is KATPIESHQVJAAEKRKC. A preparation method of the inhibitor 1 is carried out through Fmoc-protected solid-phase synthetic technology, with Rink amide MBHA resin and Fmoc-Gly-Wang resin as supporters, with 6-chloro-1-hydroxylbenzotriazole and N,N-diisopropyl carbodiimide as condensing agents, and with trifluoroacetic acid as a cutting reagent. The invention also provides an application of the inhibitor 1 for preventing or treating diabetes and complications thereof, wherein the complications comprise diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neurogenic lesion. The inhibitor 1 can be employed for preventing or treating the diabetes and the complications thereof through various dosing methods, such as subcutaneous injection or intramuscular injection, intravenous injection or intravenous drip, and oral medication, such as pills, capsules, nasal spray agent and the like. The islet amyloid polypeptide inhibitor 1 can targetedly inhibit generation of islet amyloid polypeptide, thereby preventing or treating diabetes.

Methods of inhibiting the progression of or treating secondary complications of diabetes, especially a diabetic eye disease, in a mammal by inhibiting the production of sorbitol in the mammal. Small molecule inhibitors of sorbitol production in the eye useful in the methods of the invention and pharmaceutical compositions containing the compounds, and methods of using the same.

Insulin amyloid polypeptide inhibitor, preparation method and application thereof. The invention relates to the field of drugs and particularly relates to an inhibitor 1 compound which can treat diabetes. A sequence of the inhibitor 2 is VLSVAALNHLDKATPIESH. A preparation method of the inhibitor 2 is carried out through Fmoc-protected solid-phase synthetic technology, with Rink amide MBHA resin and Fmoc-Gly-Wang resin as supporters, with 6-chloro-1-hydroxylbenzotriazole and N,N-diisopropyl carbodiimide as condensing agents, and with trifluoroacetic acid as a cutting reagent. The invention also provides an application of the inhibitor 2 for preventing or treating diabetes and complications thereof, wherein the complications comprise diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neurogenic lesion. The inhibitor 2 can be employed for preventing or treating the diabetes and the complications thereof through various dosing methods, such as subcutaneous injection or intramuscular injection, intravenous injection or intravenous drip, and oral medication, such as pills, capsules, nasal spray agents and the like. The islet amyloid polypeptide inhibitor 2 can targetedly inhibit generation of islet amyloid polypeptide, thereby preventing or treating diabetes.

The invention relates to a traditional Chinese medicine for treating diabetic eye diseases, and belongs to the field of traditional Chinese medicines for treating diabetes mellitus. The traditional Chinese medicine aims to achieve good effect and quick response. The traditional Chinese medicine is prepared from pale butterflybush flower, rehmanniae praeparatum, notoginseng root, mulberry leaf, glossy ganoderma, Chinese angelica, flos chrysanthemi and the like, has the effects of strengthening body resistance and archaeus, supplementing qi and nourishing blood, promoting blood circulation by removing blood stasis, dispelling wind and clearing liver and improving vision, and has the advantages of obvious effect, definite curative effect and quick response.

The invention provides a traditional Chinese medicine composition for treating diabetic eye disease and a preparation method thereof. The composition comprises forsythia, root of red-rooted salvia, pseudo-ginseng, medlar, and Angelica sinensis in a certain weight ratio. The composition for treating diabetic eye disease provided by the invention has reasonable formula and effects of supporting the healthy energy, promoting blood circulation to remove blood stasis, and nourishing the liver to improve visual acuity, and obvious therapeutic effect on patients with diabetic eye disease.

The invention relates to the fields of chemical pharmacy, medicinal preparations, pharmacokinetics and pharmacodynamics, specifically to a berberine-sodium caprate multi-component solid dispersion and a preparation method and pharmacological activity thereof. The berberine-sodium caprate multi-component solid dispersion is characterized in that berberine, the absorption promoting agent sodium caprate and a solid dispersion carrier are employed to prepare the berberine-sodium caprate solid dispersion, wherein berberine is dispersed in the solid dispersion in an amorphous form. The berberine-sodium caprate solid dispersion provided by the invention has the following advantages: the preparation method is simple and is easy to operate, and solubility and intestinal permeability of berberine are substantially improved, thereby improving bioavailability. The berberine-sodium caprate solid dispersion has substantial treatment effects on diabetes, diabetic complications like diabetic cardiomyopathy, diabetic great vascular complications, diabetic encephalopathy and diabetic eye diseases (retinopathy) and diseases related to diabetes. The berberine-sodium caprate solid dispersion has widely available raw materials, is convenient to use and provides a novel candidate drug for treating diabetes and complications thereof.

The invention provides a Chinese herbal compound composition for prevention or treatment of diabetic eye diseases. The composition comprises a coptidis rhizome total extract and a rhizoma zingiberis recens extract in a weight ratio of 4:1-1:1. The invention also provides a preparation method and use of the Chinese herbal compound composition. The invention further provides use of the coptidis rhizome total extract. The Chinese herbal compound composition for prevention or treatment of diabetic eye diseases has the advantages of cheap and easily available raw materials, simple preparation method and convenient drug administration. Pharmacological research results show that the coptidis rhizome total extract involved in the invention has significantly better effect in prevention and treatment of type I and type II diabetic eye diseases than a coptidis rhizome total alksloid mixture. And through combined use of the coptidis rhizome total extract and the rhizoma zingiberis recens extract,the Chinese herbal compound composition provided by the invention also has further remarkably improved effect in prevention and treatment of type I and type II diabetic eye diseases.

The invention discloses a traditional Chinese medicine for treating a diabetic eye disease, belongs to the field of the traditional Chinese medicine for treating diabetes and aims to achieve good effect and quick response. The traditional Chinese medicine is prepared from the following raw materials: honeysuckle, pseudoginseng root, rehmannia root, lucid ganoderma, Chinese angelica, hedge prinsepia nut and the like. The medicament has the effects of supporting right and banking up the root, invigorating Qi and nourishing blood, quickening the blood and transforming stasis and nourishing the liver and brightening the eyes and the advantages of remarkable effect, exact medicinal effect and quick response.

The invention discloses a Chinese medicament for treating diabetic eye diseases, which belongs to the field of Chinese medicaments for treating diabetes and has good effect and quick response. The Chinese medicament is prepared from raw materials such as fructus forsythiae, root of pseudo-ginseng, rehmannia root, glossy ganoderma, Chinese angelica, hedge prinsepia nut and the like. The Chinese medicament has the effects of supporting right and banking up the root, replenishing qi and nourishing blood, activating blood and dissolving stasis, nourishing liver and improving visual acuity, and has the advantages of remarkable effect, definite medicinal effect and quick response.

The invention relates to a medical composition based on Fushiming capsules and an application of the medical composition to treatment of diabetic eye diseases. Through research on the fingerprint spectrum of the Fushiming capsules at the early stage, 8 effective components are determined and are optimized so that the medical composition is obtained. The medical composition comprises the followingeffective components in parts by weight of 2.0-3.0 parts of 5-HMF, 8.0-10.0 parts of puerarin, 5.0-8.0 parts of 3'-methoxy puerarin, 4.0-6.0 parts of daidzin, 0.3-0.5 part of ononin, 1.0-1.5 parts ofdaidzein, 0.6-1.0 part of aurantio-obtusin and 1.4-2.0 parts of ligustilide. The medical composition has equivalent effects in the respect of preventing the retina of a diabetic rat from becoming weakto positive medicines (calcium dobesilate) and the Fushiming capsules.

The invention provides application of a chrysin derivative in medicine preparation. The chrysin derivative has a structure as shown in a formula I, and the biological activity and bioavailability of the chrysin derivative are obviously higher than those of chrysin. The chrysin derivative can be used for preparing medicines for preventing and / or treating hyperglycemia, hyperlipidemia, the Alzheimer disease (AD), senile dementia, the Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), cerebral ischemia, brain injury, obesity, diabetes and / or diabetic complications, diabetic eye diseases, diabetic nephropathy, dyslipidemia, atherosclerosis, fatty liver, non-alcoholic fatty liver disease, cirrhosis, hepatitis, obstructive jaundice, myocardial infarction and the like.

The invention discloses new application of salvianolic acid A (SAA) used in preparing drugs for preventing and treating diabetic eye diseases. A Zucker diabetic fat (ZDF) rats are induced through purina#5008 feed so as to build a diabetic model, and the intervention effect of the SAA on the diabetic eye diseases is observed. It is showed through research results that when the ZDF rats are continuously fed with the SAA for 12 weeks, the incidence rate of the ZDF rat cataract can be obviously reduced. Meanwhile, it is showed through pathology results that after the rats are fed with the SAA, the microvascular morphologies of the rat retinas are improved, and oedemata in the macular region are inhibited. Besides, it is showed through biochemistry results that when the rats are fed with the SAA, the serum transferrin level and the microalbuminuria excretion amount can be reduced, and the diabetic retinopathy is easy to prevent and treat. In a word, the SAA has the effect of improving the diabetic eye diseases, especially in the aspects of diabetic cataract, diabetic fundus arterial diseases and diabetic retina macular oedemata. The new application of the SAA is developed, and it is expected that the SAA can be used in preparation the drugs for preventing and treating the diabetic eye diseases.

The invention provides an early screening device for diabetic eye diseases, and relates to the technical field of early screening for diseases. In order to realize early screening for the diabetic eyediseases, the following technical scheme is adopted: a data processor controls an LED drive circuit to drive an LED to emit light, light rays are sequentially subjected to reflecting of a No.1 light-splitting reflecting mirror, transmission of a No.1 lens and a No.2 lens, and reflecting of a No.2 light-splitting reflecting mirror, and then are sent to the eyeballs, a CMOS sensor collects an imageof the eyeballs through a COMS focusing lens and the No.2 light-splitting reflecting mirror, the CMOS sensor sends the picture to an OLED display screen through an image sensor, a data processor anda display drive circuit, the image information displayed by the OLED display screen is focused on the No.1 light-splitting reflecting mirror through an OLED lens, the focused light is sequentially subjected to reflecting of the No.1 light-splitting reflecting mirror, the transmission of the No.1 lens and the No.2 lens, and the reflecting of the No.2 light-splitting reflecting mirror, and then sentto the eyeballs, the data processor collects the size image of the pupils, a result is obtained and is compared with the previously obtained result, and then the OLED display screen is used for realizing display.

The invention relates to a capsule for treating diabetic eye diseases. The capsule is characterized by comprising the following steps: taking the materials of astragalus membranaceus, kudzuvine root,salvia miltiorrhiza, rehmannia glutinosa, fructus corni, cortex moutan, radix paeoniae alba, chrysanthemum, angelica sinensis, lycium barbarum, herba violae and liquorice, extracting a concentrated solution, preparing extract powder, evenly mixing with centipede powder, scorpion powder, dried ground beetle powder, cicada slough powder and pearl powder, then drying, sterilizing, and packaging in the capsule, thereby obtaining the capsule for treating the diabetic eye diseases.

The invention relates to the field of medicines and in particular relates to a silkworm pupa polypeptide 2 which can be used for preventing or treating diabetes mellitus. The sequence of the polypeptide 2 is PYERQADEPETKVTKKI. A preparation method of the polypeptide 2 comprises the following steps: (1) decoction; (2) enzymolysis; (3) protein separation; (4) separation and purification through semipreparative RP-HPLC (reverse phase high-performance liquid chromatography); (5) freeze-drying, wherein neutral protease and compound protease are adopted for enzymolysis; macroporous resin and sephadex are adopted for protein separation. The invention provides the application of the polypeptide 2 to treatment of diabetes mellitus and complications of diabetes mellitus, wherein the complications of diabetes mellitus include diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neuropathy. The silkworm pupa polypeptide 2 is extracted from silkworm pupae, has good safety and can be used for effectively preventing or treating diabetes mellitus.

The invention discloses new application of salvianolic acid A (SAA) used in preparing drugs for preventing and treating diabetic eye diseases. A Zucker diabetic fat (ZDF) rats are induced through purina#5008 feed so as to build a diabetic model, and the intervention effect of the SAA on the diabetic eye diseases is observed. It is showed through research results that when the ZDF rats are continuously fed with the SAA for 12 weeks, the incidence rate of the ZDF rat cataract can be obviously reduced. Meanwhile, it is showed through pathology results that after the rats are fed with the SAA, the microvascular morphologies of the rat retinas are improved, and oedemata in the macular region are inhibited. Besides, it is showed through biochemistry results that when the rats are fed with the SAA, the serum transferrin level and the microalbuminuria excretion amount can be reduced, and the diabetic retinopathy is easy to prevent and treat. In a word, the SAA has the effect of improving the diabetic eye diseases, especially in the aspects of diabetic cataract, diabetic fundus arterial diseases and diabetic retina macular oedemata. The new application of the SAA is developed, and it is expected that the SAA can be used in preparation the drugs for preventing and treating the diabetic eye diseases.

The invention belongs to the field of traditional Chinese medicines for treating diabetes, and relates to a traditional Chinese medicine for treating diabetic eye diseases. The traditional Chinese medicine has good effect and quick action and is prepared from Chinese thorowax root, sanchi, rehmannia root, lucid ganoderma, Chinese angelica root, hedge prinsepia nut and other raw materials. The traditional Chinese medicine has the effects of reinforcing body resistance, invigorating qi, promoting blood circulation, dispelling blood stasis, nourishing liver and improving eyesight; and has the advantages of remarkable effect, definite drug effect and quick action.

The invention discloses an application of anthracene nucleus antibiotic and its pharmaceutical salt for treating diabetic eye diseases. The invention found that the anthracene nucleus antibiotic and its pharmaceutical salt have good effect on treatment of diabetic eye diseases, and especially the anthracene nucleus antibiotics can be prepared to prolonged action preparations such as a nano preparation, a microballoon preparation, liposome and hydrogel, the toxicity of anthracene nucleus antibiotic is reduced, and the anthracene nucleus antibiotic enables ophthalmic administration, administration dosage is simultaneously enlarged, the duration time of drug effect is long, the medicament curative effect is stronger than that of the common preparations of the anthracene nucleus antibiotic, when the ophthalmic administration is carried out, the anthracene nucleus antibiotic has good treatment effect for treating various eye diseases relative to diabetes, the medicine treatment is carried out when the diabetic eye diseases is found at initial stage, the deterioration of diseases can be avoided, the active treatment effect is provided, so that a surgery treatment method with large wound such as operation can be avoided.

The invention provides a traditional Chinese medicine compound composition for preventing or treating diabetic eye disease, which comprises the total extract of Coptis chinensis and the extract of ginger, wherein the weight ratio of the total extract of Coptis chinensis and the extract of ginger is 4:1-1 :1. The invention also provides the preparation method and application of the traditional Chinese medicine compound composition. The present invention further provides the use of the total extract of Coptidis rhizome. The traditional Chinese medicine compound composition for preventing or treating diabetic eye disease of the present invention has cheap and easy-to-obtain raw materials, simple preparation method and convenient administration. The results of pharmacological studies show that the total extract of Coptis chinensis of the present invention has a significantly better effect than the total alkaloid mixture of Coptis chinensis on the prevention and treatment of type I and type II diabetic eye diseases, and the Chinese medicine compound composition of the present invention is obtained by combining the total extract of Coptis chinensis When used in combination with ginger extract, it also has a significantly improved effect of preventing and treating type I and type II diabetic eye diseases.

The invention relates to a traditional Chinese medicine for treating diabetic eye disease, belonging to the field of traditional Chinese medicine for treating diabetes, aiming at good effect and quick effect. The medicine of the invention is prepared by adopting raw materials of isatis root, pseudo-ginseng, rehmannia, lucid ganoderma, Chinese angelica and nux prinsepiae, the medicine has the effects of strengthening healthy energy, tonifying qi and nourishing the blood, promoting blood circulation and removing blood stasis as well as nourishing the liver to improve visual acuity, and the medicine has the advantages of obvious effect, definite effect and quick effect.

The invention discloses an application of anthracene nucleus antibiotic and its pharmaceutical salt for treating diabetic eye diseases. The invention found that the anthracene nucleus antibiotic and its pharmaceutical salt have good effect on treatment of diabetic eye diseases, and especially the anthracene nucleus antibiotics can be prepared to prolonged action preparations such as a nano preparation, a microballoon preparation, liposome and hydrogel, the toxicity of anthracene nucleus antibiotic is reduced, and the anthracene nucleus antibiotic enables ophthalmic administration, administration dosage is simultaneously enlarged, the duration time of drug effect is long, the medicament curative effect is stronger than that of the common preparations of the anthracene nucleus antibiotic, when the ophthalmic administration is carried out, the anthracene nucleus antibiotic has good treatment effect for treating various eye diseases relative to diabetes, the medicine treatment is carried out when the diabetic eye diseases is found at initial stage, the deterioration of diseases can be avoided, the active treatment effect is provided, so that a surgery treatment method with large wound such as operation can be avoided.